Drop Two, Add One: Vertex Adjusts Adaptive Trial Seeking An All-Oral HCV Regimen
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Vertex Pharmaceuticals, Inc., is adjusting an ongoing trial that tests its potential first-in-class protease inhibitor telaprevir in combinations it hopes will lead to an all-oral cocktail that is effective against genotype 1 hepatitis C, the firm announced Dec. 21.